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Background:  Atrial  ﬁbrillation  (AF)  and  heart  failure  (HF)  are  associated  with  signiﬁcant  mortality  and
morbidity.  We  sometimes  encounter  patients  who  have  AF  upon  admission  to the  hospital,  but it  spon-
taneously  converts  to sinus  rhythm  within  several  days  (i.e.  converter).
Purpose:  We  examined  the association  between  the  outcome  and  types  of  strategy  for  AF  treatment  in
converters.
Methods:  From  January  2000  to  December  2005,  we  identiﬁed  95  converters  (age  69  ±  12  years)  pre-
senting  with  worsening  HF  and  AF upon  admission,  in  which  sinus  rhythm  was  restored  within  7 days
without  either  electrical  or pharmacological  cardioversion.  The  patients  were  classiﬁed  into  three  groups
according  to the  antiarrhythmic  drug  (AAD)  therapy  used:  class  I AAD,  class  III  AAD,  and rate-control  drug.
The  patients  were  followed  for  36  ±  23  months.
Results:  The  left ventricular  ejection  fraction  (LVEF)  signiﬁcantly  improved  with  conversion  to  sinus
rhythm  (38  ±  14%  vs. 47  ± 13%,  p  < 0.05).  Those  receiving  class  I AAD  had  a trend  toward  a well-preserved
LVEF  (50  ± 13%,  n  =  35) as  compared  to those  receiving  class  III  AAD  (43 ± 12%,  n  = 24)  or  rate-control
drug  (47  ± 14%, n =  36).  In the  patients  receiving  class  I AAD,  the  rate  of  all-cause  death  increased  1.9-fold
(p  =  0.009)  compared  to those  receiving  class  III AAD,  and  1.7-fold  (p = 0.010)  compared  to those  taking
rate-control  drug.  A  hospitalization  for HF  was  observed  in 49 (52%)  patients,  however  there  was  no
signiﬁcant  difference  in  the  rate  of hospitalization  among  the  three  groups  (p  = 0.890).  Those  receiving
rate-control  drugs  had  a 50%  lower  rate  of  the  development  of  persistent  AF  than  those  taking  class  III
AAD (p = 0.019).
Conclusions:  A  rate-control  strategy  should  be  the  primary  approach  for converters  to reduce  mortality
and  development  of  persistent  AF.
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Atrial ﬁbrillation (AF) and heart failure (HF) have been recog-
ized as major and increasing public health issues in industrialized
ountries with an aging population. AF and HF often co-exist,
nd both are associated with signiﬁcant morbidity and mortality
1–3]. The prevalence of AF increases in proportion to the sever-
ty of HF, ranging from between 10% and 20% in mild-to-moderate
F up to 50% in severe HF [4].  Recently, in the Atrial Fibrillation
nd Congestive Heart Failure trial [5] the rhythm-control strat-
gy was compared with the rate-control strategy in patients with
eft ventricular dysfunction or HF, and a history of AF. This trial
∗ Corresponding author. Tel.: +81 562 93 2312; fax: +81 562 93 2315.
E-mail address: enwatan@fujita-hu.ac.jp (E. Watanabe).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
oi:10.1016/j.jjcc.2012.01.022anese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
demonstrated that there was  no signiﬁcant difference in the rate of
death from cardiovascular causes with the rhythm-control strategy
as compared with the rate-control strategy.
Persistent AF often leads to an acute exacerbation of HF, and
restoration of sinus rhythm using cardioversion or catheter abla-
tion increases the systolic function and improves HF. This reversible
form of HF is referred to as tachycardia-induced cardiomyopathy
(TIC) and is primarily conﬁned to patients free of structural heart
disease. We  sometimes, however, encounter patients who  had HF
with AF at the time of admission to the hospital but it sponta-
neously converts to sinus rhythm within several days. There is
currently limited information available on the clinical outcome or
optimal antiarrhythmic strategy in such patients who had wors-
ening HF associated with paroxysmal AF upon admission to the
hospital. In the present study we  deﬁned those patients as “convert-
ers” and aimed to examine the outcome, and the effect of long-term
vier Ltd. All rights reserved.
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reatment with either the rhythm-control strategy or the rate-
ontrol strategy on mortality, hospitalization for worsening HF, and
rogression into persistent AF.
ethods
tudy cohort
From January 2000 to December 2005, we enrolled consecutive
atients who were hospitalized for overt clinical decompensation
f HF to our hospital. Patients were excluded if they had one or
ore of the following ﬁndings: patients in whom HF or AF devel-
ped after admission, those ≥95 years or <20 years of age, and those
ith severe primary pulmonary disease, congenital heart disease,
ctive myocarditis, renal failure requiring dialysis, or malignancy.
n addition, patients were excluded if, within the previous two
onths, they had undergone coronary revascularization or had an
cute myocardial infarction, unstable angina, or cerebral ischemic
vent. We  also excluded patients who had either electrical or phar-
acological cardioversion, catheter ablation for AF or atrial ﬂutter,
nd patients with an implanted cardiac pacemaker.
Patients were classiﬁed into three groups according to the types
f the strategy for AF treatment upon hospital discharge: class I
ntiarrhythmic drug (AAD), class III AAD, and rate-control drug.
rug therapy was at the discretion of the physician in charge and
as not randomly allocated. The study protocol was approved by
he ethical committee of our institution. All patients provided writ-
en informed consent.
aboratory tests
Laboratory tests including 12-lead electrocardiogram (ECG), 24-
 Holter ECG, blood tests, and two-dimensional echocardiography
ere performed at the time of admission to the hospital and before
ischarge. A single echocardiographer who was blinded to the clini-
al information performed off-line echocardiographic analysis. Left
entricular ejection fraction (LVEF) was calculated by the biplane
impson’s method of discs. Mean heart rate was obtained from 24-h
olter ECG. Recurrence of AF or atrial ﬂutter was assessed via data
rom snapshot ECGs assessed at 1 and 3 months after discharge
rom hospital and every 2 months thereafter.
eﬁnition
A “converter” was deﬁned as a patient who had AF upon admis-
ion to the hospital, in which sinus rhythm was restored within 7
ays without either electrical or pharmacological cardioversion.
ollow-up and endpoints
Research coordinators and physicians recorded baseline data
or all patients at the time of enrollment including patient demo-
raphics, past medical conditions, and current medication. During
he follow-up period, patients or their families were periodically
ent a questionnaire and interviewed by telephone. Members
f the events veriﬁcation committee who were blinded to the
AD therapies reviewed medical records pertaining to death or
ospitalization. If this was not possible, the causes of death or hos-
italization were determined by direct communication with the
atients’ general practitioners or families.
The study endpoints were all-cause death, cardiovascular death,
ospitalization for worsening HF, and development of persistent AF
duration longer than 1 week). Cardiovascular death included death
ue to worsening HF, sudden death, acute myocardial infarction,
ortic dissection, and systemic embolism. HF death was deﬁned as
 death resulting from multiorgan failure caused by progressionrdiology 60 (2012) 31–35
of  pump failure. Sudden death was deﬁned as either a witnessed
cardiac arrest or death within 1 h after the onset of acute symptoms,
or an unexpected death in a patient known to have been well within
the previous 24 h. Hospitalization for HF was deﬁned as the need
for intravenous administration of diuretics.
Statistical analysis
Differences in baseline characteristics between groups were
determined using the chi-square test or Fisher’s exact t-test for
categorical data. Differences in the baseline characteristics among
three groups were tested using one-factor analysis of variance with
the Bonferroni post hoc test. The associations of the clinical factors
with the endpoints were analyzed using the univariate and multi-
variate Cox proportional-hazards regression model and presented
as hazard ratio (HR) and 95% conﬁdence interval (CI), with class III
AAD use considered the reference. Next, independent predictors of
the endpoints in converters were analyzed using the multivariate
Cox proportional-hazards regression model. Time-to-event rates
for endpoints were estimated by the Kaplan–Meier method and
compared by the log-rank test. Survival analyses were performed
according to the intention-to-treat principle. For skewed distribu-
tion, B-type natriuretic peptide (BNP) was  transformed to natural
logarithm. Quantitative data are expressed as means ± standard
deviation (SD) values. A two-tailed p-value of <0.05 was considered
signiﬁcant.
Results
During the recruitment period, 704 consecutive HF patients
were assessed for enrollment eligibility. Among them we identi-
ﬁed 95 converters, and they had spontaneous conversion to sinus
rhythm within 3.1 ± 2.0 days after admission.
Baseline clinical characteristics of the patients according to
antiarrhythmic strategies
The baseline demographic and clinical characteristics of the
three groups of patients classiﬁed according to AAD therapy at
hospital discharge are listed in Table 1. Of the 95 converters, 35
(37%) patients received class I AAD, which included aprindine
(n = 27, mean dosage 36 ± 8.5 mg/day), propafenone (n = 7, mean
dosage 300 ± 87 mg/day), and ﬂecainide (n = 1, 100 mg/day). Class
III AAD, which included amiodarone (n = 20, mean dosage:
111 ± 40 mg/day) and sotalol (n = 4, mean dosage 35 ± 10 mg/day),
was given to 24 (25%) patients. The remaining 36 (38%) patients
received rate-control drugs; of these patients, 18 (50%) received
-blocker, 5 (14%) received digoxin, and the remaining 13 (36%)
received both -blocker and digoxin. No patients received non-
dihydropyridine calcium-channel blockers. Before admission to the
hospital, no patients had received -blocker for the purpose of
rate-control therapy. The mean heart rate decreased from 108 ± 32
beats/min at admission to 69 ± 15 beats/min at discharge (p < 0.01).
No patients restored sinus rhythm during Holter ECG recording
performed at the time of admission to the hospital. The LVEF at
discharge signiﬁcantly improved as compared to those at admis-
sion (38 ± 14% vs. 47 ± 13%, n = 95, p < 0.05). Those receiving class
I AAD had a trend toward well-preserved LVEF (50 ± 13%) at dis-
charge as compared with those receiving class III AAD (43 ± 12%)
or rate-control drugs (47 ± 14%). They also had a lower prevalence
of ischemic HF (p < 0.001) and lower BNP (p = 0.011). Patients taking
rate-control drugs were more likely to have ischemic HF and lower
BNP as compared to those who  received class III AAD. Notably,
patients taking class III AAD exhibited a lower mean heart rate
(63 ± 10 beat/min) and fewer treatments with -blockers as com-
pared with those receiving class I AAD or rate-control drugs.
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Table  1
Clinical characteristics of the converters according to antiarrhythmic therapy.
Class I AAD (n = 35) Class III AAD (n = 24) Rate-control drug (n = 36) p-Value
Age, years 67 ± 11 65 ± 11 72 ± 13 0.059
Sex,  Male/female, % 63/37 73/17 58/42 0.237
NYHA class (I/II/III/IV), n 28/4/3/0 18/2/4/0 27/6/3/0 0.721
Diabetes mellitus, % 19 25 33 0.141
Hypertension, % 48 33 36 0.107
History of stroke, % 6 8 8 0.598
HF  etiology, % ischemic 6 47 67 <0.001
No  underlying heart disease, % 11 8 8 0.571
LVEF,  % 50 ± 13 43 ± 12 47 ± 14 0.129
LAD,  mm 42 ± 8 41 ± 7 39 ± 8 0.373
Heart  rate, beat/min 71 ± 15b 63 ± 10 72 ± 16* 0.039
Systolic blood pressure, mmHg  113 ± 21 108 ± 14 111 ± 17 0.487
Diastolic blood pressure, mmHg  64 ± 12 62 ± 10 63 ± 13 0.727
ECG  ﬁndings
QRS duration, ms 102 ± 14 119 ± 30 113 ± 24 0.046
QT  interval, ms 390 ± 53 421 ± 66 389 ± 62 0.105
QTc  interval, ms  432 ± 46 442 ± 50 415 ± 48 0.095
BNP,  pg/mL 214 ± 200b 510 ± 537 230 ± 236* 0.011
Medications, %
-Blocker 80 55 87 0.013
ACE-I/ARB 82 83 75 0.682
Loop  diuretics 92 83 78 0.260
Spironolactone 48 63 58 0.487
Digoxin 63 42 50 0.260
Dihydropyridine CCB 6 8 3 0.070
Nitrate 19 34 36 0.170
Statin 14 38 17 0.063
Antiplatelet 77 75 63 0.382
Warfarin 30 54 22 0.032
Data represent means ± SD or frequency. AAD, antiarrhythmic drug; HF, heart failure; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; ECG, electrocardiogram;
NYHA,  New York Heart Association; QTc, rate-corrected QT interval; BNP, B-type natriuretic peptide; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II
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* Class III AAD vs. rate-control drug, p < 0.05.
b Class I AAD vs. class III AAD, p < 0.05.
During the study, one patient taking amiodarone crossed over
o the rate-control drug due to liver dysfunction, and 2 patients
aking class I AAD crossed over to the rate-control drug because of
orsening HF. Two patients receiving rate-control drug were added
lass III AAD to maintain sinus rhythm.
ndpoints
Fig. 1 shows Kaplan–Meier survival curves in relation to the
ntiarrhythmic strategies and endpoints. Table 2 presents the HRs
f the endpoints adjusted for differences in age, sex, and ischemic
tiology of HF. Patients were followed for 36 ± 23 months. The rates
f all-cause death (Fig. 1A) and cardiovascular death (Fig. 1B) were
igniﬁcantly higher in patients who received class I AAD as com-
ared to those who received class III AAD or rate-control drugs
Table 2). There was no signiﬁcant difference in the rates of all-
ause death and cardiovascular death between class III AAD and
ate-control drugs (Fig. 1A and B). The details of the cardiovascu-
ar deaths was  as follows: class I AAD (HF, n = 9; sudden death,
 = 2; systemic embolism, n = 1; and acute myocardial infarction,
 = 2); class III AAD (HF, n = 2; sudden death, n = 1; and aortic dissec-
ion, n = 1); and rate-control drugs (HF, n = 1; sudden death, n = 2;
able 2
djusted hazard ratio of endpoints according to the antiarrhythmic strategies.
Endpoint Class I AAD (n = 35) 
n (%) HR (95% CI) p-Value
All-cause death 15 (43) 1.87 (1.10–2.89) 0.009 
Cardiovascular death 14 (40) 1.68 (1.04–2.97) 0.010 
Hospitalization for HF 17 (48) 0.91 (0.61–1.38) 0.658 
Development of persistent AF 13 (37) 0.97 (0.61–1.57) 0.900 
AD, antiarrhythmic drug; HF, heart failure; AF, atrial ﬁbrillation; HR, hazard ratio; CI, cosystemic embolism, n = 1; and acute myocardial infarction, n = 1).
There was a signiﬁcant difference in the prevalence of death due to
worsening HF among the three groups (log-rank test, p = 0.017), but
the prevalence of sudden death was not different among the three
groups (log-rank test, p = 0.507). During the study, 49 (52%) patients
were hospitalized due to worsening HF. The rate of hospitalization
was not different among the three groups (class I AAD: 48%; class
III AAD: 54%; and rate-control drug: 52%; log-rank test, p = 0.890)
(Fig. 1C). Development of persistent AF is shown in Fig. 1D.  The
3-year cumulative rate of progression was  26%. The rate of devel-
opment of persistent AF was  signiﬁcantly lower in patients treated
with rate-control drugs (11%) compared to those who received class
I AAD (37%) or those who  received class III AAD (33%) (log-rank test,
p = 0.021).
The independent predictors of the endpoints in 95 converters
was assessed by multivariate Cox proportional-hazards regression
modeling after adjusting for age, sex, New York Heart Associa-
tion (NYHA) class, ischemic etiology of HF, LVEF, BNP, class I AAD,
class III AAD, and -blocker use. The adjusted HRs for all-cause
death were 5.74 (95%CI: 1.09–43.8, p = 0.039) for male sex, 14.6
(95%CI: 2.44–114, p = 0.002) for class I AAD, 8.40 (95%CI: 1.67–48.4,
p = 0.011) for NYHA class, and 7.84 (95%CI: 2.79–31.7, p < 0.001) for
Class III AAD (n = 24) Rate-control (n = 36)
 n (%) n (%) HR (95% CI) p-Value
4 (17) 1 7 (19) 1.08 (0.55–1.98) 0.815
4 (17) 1 5 (14) 1.17 (0.58–2.22) 0.631
13 (54) 1 19 (52) 1.08 (0.73–1.56) 0.689
8 (33) 1 4 (11) 0.50 (0.26–0.89) 0.019
nﬁdence interval. Class III AAD was taken as a reference.
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Fig. 1. Kaplan–Meier survival curves according to the antiarrhythmic treatment in converter. (A) All-cause death. Patients who received class I antiarrhythmic drug (AAD)
exhibited higher mortality as compared to those who received class III AAD or rate-control drugs. (B) Cardiovascular death. Patients taking class I AAD had higher mortality
as  compared to those who  received class III AAD or rate-control drugs. (C) Hospitalization for heart failure. There was no signiﬁcant difference in the rate of hospitalization
among  the three groups. (D) Development of persistent atrial ﬁbrillation. The rate of progression into persistent atrial ﬁbrillation was signiﬁcantly lower in patients treated
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ndicates class I AAD. (For interpretation of the references to color in this ﬁgure leg
NP. The independent predictors of cardiovascular death were BNP
HR 7.33, 95%CI 2.2–28.7, p < 0.001), NYHA class (HR 11.9, 95%CI
.22–93.3, p = 0.004), and class I AAD (HR 24.6, 95%CI 3.43–298,
 = 0.001). The adjusted HR for hospitalization for HF was  NYHA
lass (HR 0.40, 95%CI 0.14–0.97, p = 0.04). Finally, the independent
redictors of the development of persistent AF were LVEF (HR 0.95,
5%CI 0.90–0.99), BNP (HR 0.59, 95%CI 0.36–0.98, p = 0.04), class I
AD (HR 4.41, 95%CI 1.21–19.1, p = 0.02), and class III AAD (HR 6.53,
5%CI 1.44–38.4, p = 0.014).
iscussion
We  examined the association between antiarrhythmic strate-
ies and the mortality and morbidity in patients with worsening
F associated with AF upon admission to the hospital, but it spon-
aneously converted to sinus rhythm within 7 days (i.e. converter).
lthough converters taking class I AAD exhibited relatively well-
reserved LVEF, the survival rate was lower as compared with those
aking class III AAD or rate-control drugs. The rate of hospitaliza-
ion for HF, however, was not different among the three groups
f antiarrhythmic strategies. And ﬁnally, the rate of progression to
ersistent AF was lower in those receiving rate-control drugs as
ompared to those taking class I AAD or class III AAD.ue line indicates rate-control drug, green line indicates class III AAD, and red line
e reader is referred to the web version of the article.)
AF can lead to HF, and HF can lead to AF. The treatment of
patients with HF and AF presents speciﬁc challenges. In the present
study we focused on the converters who have AF upon admis-
sion to the hospital, but it spontaneously converts to sinus rhythm
within several days. The LVEF signiﬁcantly improved with sponta-
neous conversion to sinus rhythm. Those patients, however, were
distinct from classic TIC [6–10] in regard to experiencing sponta-
neous conversion to sinus rhythm and the presence of underlying
heart disease in the majority of the converters. It is difﬁcult to
determine whether AF observed at admission to the hospital was
a cause rather than a consequence of HF, and there is currently
limited information available on the optimal antiarrhythmic strat-
egy in the converters. We  then sought to determine the association
between the outcome and types of the strategy for AF treatment in
the converters.
The converters who  received class I AAD had a worse progno-
sis mainly due to cardiovascular death, although they had relatively
well-preserved LVEF and were less likely to have ischemic HF. Mul-
tivariate Cox proportional-hazards regression analysis revealed
that the independent predictors of cardiovascular death were BNP,
NYHA class, and class I AAD use. The class I AAD mostly used here
for the converters was  aprindine, which has less potent Na+ channel
blocking activity and is recommended by the guidelines published
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[21] Wilton SB, Fundytus A, Ghali WA,  Veenhuyzen GD, Quinn FR, Mitchell LB, HillE. Watanabe et al. / Journa
y the Japanese Circulation Society [11,12]. Previous studies sug-
ested that class I AAD treatment was associated with enhanced
ortality in patients with AF and HF with low LVEF [13,14].  In a
etrospective analysis from the Stroke Prevention Atrial Fibrillation
rial, Flaker et al. [13] reported increased mortality in HF patients
aking class Ia AAD and class Ic AAD. Stevenson et al. [14] have
oted that patients who have low LVEF and AF treated with class I
AD had worse 2-year survival and sudden death rates than a group
reated with amiodarone. Recently, data from the Mayo Clinic reg-
stry [15] and Bhahita et al. [16] demonstrated that approximately
0% of patients with HF have a normal or near-normal LVEF, and
heir prognosis appears to be only marginally better than that of
atients with HF and reduced LVEF. In addition, patients with HF
nd preserved LVEF are older and more likely to have AF as com-
ared with patients with HF and reduced LVEF. Our data, in addition
o these previous studies, suggest that physicians treating convert-
rs should avoid the use of class I AAD for the maintenance of sinus
hythm even if they appeared to have normal or near-normal LVEF.
We found that there was no signiﬁcant difference in the rate of
ospitalization for HF among the three treatment groups, which
as similar to the result of a previous study [5].  This observation
uggests that the maintenance of sinus rhythm does not prevent
ospitalization for HF, and that adequate HF regimens [17] are more
mportant than rhythm management in the converters.
Strict or lenient heart rate control in patients with HF and a
istory of AF is a matter of concern. A recent study by van Gelder
t al. [18] demonstrated that lenient heart rate control was not
nferior to strict rate control in the prevention of major cardiovas-
ular events in patients with permanent AF, in which only 9.8% of
atients with a history of hospitalization for HF were included. In
he nature of this study we did not predeﬁne the target heart rate
nd we could not examine the association between the target heart
ate and cardiovascular events.
The present study showed that the rate of progression of per-
istent AF was 8.8%/year, which was similar to those in recent
tudies [19,20] that identiﬁed advanced age and HF as the potent
isk factors for AF perpetuation. The independent predictors of the
evelopment of persistent AF in this study were low LVEF, higher
NP, class I AAD and class III AAD use, suggesting a rate-control
trategy with adequate HF treatment may  be recommended to
educe the development of persistent AF.
In the present study we did not enroll patients who underwent
atheter ablation for AF. A recent meta-analysis of catheter ablation
or AF and HF showed that absolute improvement in LVEF was 11%,
nd the rate of recurrence of AF seemed similar in those with HF
ersus those without HF, but multiple procedures are more often
equired in those with HF [21]. This study highlights the need for
rospective, randomized studies to conﬁrm the effect of ablation
nd delineate the patient subgroups that will beneﬁt from it.
tudy limitations
The present study has several limitations. Our analysis was
ased on the retrospective observation of a small cohort of patients
t a tertiary institution, which may  constitute a selection bias.
he types of the strategy were at the discretion of the physician
n charge and were not randomly allocated, which may  also
onstitute a selection bias. The association between target heart
ate and outcomes was not examined in the rate-control strategy
atients. In HF patients, hemodynamic or electrophysiological
ariables can be changed by several factors, such as the etiology
nd stage of HF or the therapeutic interventions applied over
ime. Although snapshot ECGs are a standard method of assessing
he maintenance of sinus rhythm, they may  underestimate the
ecurrence of asymptomatic AF.rdiology 60 (2012) 31–35 35
Conclusions
Our data suggest that a rate-control strategy should be the
primary approach for converters to reduce the mortality and pro-
gression into persistent AF.
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